New research involving 31,041 adults with type 2 diabetes suggests that dihydropyridine calcium-channel-blockers (DCCBs), a common class of blood pressure medication, may be associated with a 33% higher risk of major adverse kidney events. This finding raises questions about the long-term safety of using these drugs as secondary treatments for hypertension in patients already receiving modern kidney-protective therapies.
The 33% Risk Increase: What the Data Shows
For years, managing blood pressure has been a cornerstone of slowing diabetic kidney disease (DKD). However, a recent study led by researchers at Rabin Medical Center and Tel Aviv University has uncovered a concerning correlation. The study tracked adults with type 2 diabetes between 2016 and 2021 who were already using renin-angiotensin system inhibitors (RASi) and SGLT2 inhibitors (SGLT2i) to manage their health.
Of the 31,041 participants, 11,841 (38.1%) were also prescribed DCCBs. During a median follow-up period of 3.5 years, researchers found that this group faced a significantly higher risk of major adverse kidney events compared to the 19,200 patients (61.9%) using non-DCCB therapies. Specifically, the risk of these adverse events was 33% higher for those on DCCBs.
Benaya Rozen-Zvi, MD, the principal investigator and Director of the Nephrology Department at Rabin Medical Center, emphasized the gravity of these findings. “Selecting the appropriate antihypertensive treatment is critical, as it can directly influence the rate of kidney disease progression,” Dr. Rozen-Zvi stated, noting that over 80% of patients with chronic kidney disease (CKD) also struggle with hypertension.
Why Recent Research Conflicts with Past Studies
This latest data presents a striking contrast to previous medical literature. A 2022 study involving nearly 20,000 type 2 diabetes patients suggested that DCCBs might actually decrease the risk of advanced chronic kidney disease or end-stage renal disease. This discrepancy highlights the complexity of managing multi-morbid patients.
The current study, however, focused on those receiving “modern kidney-protective therapies” (RASi and SGLT2i) and found that adding DCCBs as a second or third-line treatment might counteract some of those protections. Timna Agur, the study’s lead author from the Gray Faculty of Medical and Health Sciences at Tel Aviv University, noted that these findings “raise important questions about whether these medications are always the best option” for this specific patient population.
The Challenge of Confounding Factors
Medical experts caution that these results are not yet definitive. Because this was an observational study, researchers cannot rule out “residual confounding” or “indication bias.” This means the reasons why a doctor chose a specific medication for a patient might be linked to the very risks being studied, potentially skewing the data.
Future Trends in Hypertension and Kidney Management
As clinicians digest this data, several trends are likely to emerge in the management of diabetic and hypertensive patients. The medical community is shifting toward more personalized, highly scrutinized prescribing patterns to avoid unintended consequences in kidney health.
- Increased Scrutiny of Second-Line Agents: Instead of reflexively prescribing DCCBs when first-line treatments fail to meet blood pressure targets, doctors may lean more heavily on alternatives like thiazide diuretics.
- Expanded Clinical Trials: The research team is already planning studies to see if these trends hold true in non-diabetic populations, which could redefine hypertension guidelines globally.
- Rigorous Monitoring Protocols: For patients remaining on combination therapies, there will likely be a greater emphasis on monitoring the glomerular filtration rate (GFR) and serum electrolytes.
Frequently Asked Questions
What are DCCBs?
Dihydropyridine Calcium Channel Blockers (DCCBs) are a class of medication widely used to treat high blood pressure (hypertension).
Should I be worried if I am taking DCCBs?
Not necessarily. The study was observational and requires replication in larger, prospective cohorts. You should continue your current regimen unless your doctor advises otherwise.
What are the alternatives mentioned in the study?
Thiazide diuretics were identified as a safe and effective option that can be used alongside RASi and SGLT2i therapies, though they require careful monitoring of kidney function.
To stay updated on the latest medical research and health management strategies, [subscribe to our newsletter] or explore our [latest articles on diabetes care].
What do you think about the shift in blood pressure management? Let us know your thoughts in the comments below!
Related reading